Ultragenyx Pharmaceutical Inc.
Resume Phase 1/2 study for GTX-102
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 11 Jan 2021
- Due
- 30 Jun 2021
- Delivered
- Q2 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“The study is expected to resume enrollment and dosing in the first half of 2021”
What we found
Evidence strength A What the grades mean
The company resumed the Phase 1/2 study for GTX-102 in Canada and the U.K. during the second quarter of 2021, meeting the first-half deadline.
-
A Ultragenyx Pharmaceutical Inc. 10-K filed 2022-02-15
“In the second quarter of 2021, we and our partner GeneTx announced that Health Canada (HC) cleared a protocol amendment and the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) approved a Clinical Trial Application (CTA) to begin treatment” ✓ confirmed on the page
Market reaction: the shares moved -5.2% against the S&P 500 over the three sessions around the disclosure (14 Feb 2022 to 17 Feb 2022). What this measures
Checked 24 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Project other
- Indicative materiality
- Low rules
- Action
- Resume
- Deliverable
- Phase 1/2 study for GTX-102
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Low
- Specificity
- High
- Conditional
- Yes: following resolution of FDA requests and approval to proceed
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: disagreesClaude (Anthropic) re-read the evidence blind and read it as “Late”.
- Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and agrees with the second check.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Ultragenyx Pharmaceutical Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-RARE-021425 · Corrections policy